## DMPA – DM type I. Pocket Assistant

(C) 2012 BIONICSOFTWARE S.R.O. JIŘÍ SLAVÍK

Who is the most experienced inventor? Nature.

**Bionics** inspires in the nature to design modern <u>technology</u>.

## Basic goals

- Expert system on mobile platform to actively support DM type I. therapy
- Monitoring system providing analysis for therapy optimization
- Innovations of CGM implementations
- Innovations of Insulin Management System implementations
- Development of autonomous sensors placed constantly in human tissue

## Scope and phases

### **DMPA** road map

#### • LEVEL 1

Therapy planner

Monitoring system

Alerting system

Reporting engine

#### • LEVEL 2

All DMPA level 1, features

**CGM** synchronization

Individual model calculation

Computed CGM (C-CGM)

Expert system provider

#### • LEVEL 3

All DMPA level 2. features

Implanted CGM device (long-term/constant)

**Optional** sensors

Management of optimized insulin distribution

# bionicSOFTWARE s.r.o. phases

#### PHASE I.

Bring to live

#### May 16, 2012

By most estimates, the mobile health apps market is a gold mine. It will see revenue grow from \$230 million in 2010 to \$392 million in 2015, according to Frost & Sullivan.

#### PHASE II.

Collect industry and marketing data

Focus on innovations

Contest on mobile health apps market

#### PHASE III.

Go inside human

#### Nanobiotechnology and Biointeractions Research group in CEITEC:

CEITEC is a project aiming to set up a Central European centre of scientific excellence in Brno

#### • PHASE IV.

Derived products of autonomous sensors and actuators inside human body

### Opportunities

### Target customers

DM type I. patients (young and active people)
Parents of DM type I. children
Doctors/therapists [optional, patient management system]
Diabetes clinics [optional, patient management system]

### Target markets

EU countries US Worldwide

### Derived products

Top leading Diabetes Technology & Therapeutics companies

## Epidemiology / Market numbers

### Worldwide

11 – 22 M patients worldwide


**Increasing 400k U14 each year** 

### • EU + NA

+ 8-17 new patients per each 100.000 habitants per year Examples:

- **CZE:** 800 1700 new patients per year
- **SVK**: 400 850 new patients per year
- **DEU**: 6500 14000 new patients per year
- *USA*: 24000 51000 new patients per year

## DM type I. therapy with DMPA



## Simple architecture

